Cite

HARVARD Citation

    Garon, E. et al. (2018). Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung cancer. pp. 91-98. [Online]. 
  
Back to record